Novartis Bioventures Ltd, 10% Owner at Aeglea BioTherapeutics, Inc. (AGLE), sold 19,550 shares at $10.06 ($197K) on 2018-05-11, disclosed to the SEC on 2018-05-14.
Open-market sale of $197k AGLE by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| Filing → |
| GRTX | SELL | 2020-06-04 | $251K | — | Filing → |
| BCYC | BUY | 2019-05-30 | $2.4M | — | Filing → |
| ARPO | SELL | 2019-04-15 | $185K | — | Filing → |